Peer-reviewed veterinary case report
New chemotherapy drug tested for dogs with mammary cancer tolerance
By Kristiansen, V M et al.·Published in Veterinary and comparative oncology·2017·Department of Companion Animal Clinical Sciences·View original on PubMed →
PetCaseFinder translated the abstract of this peer-reviewed paper into plain English so pet owners can read it. We do not publish original research — every detail traces back to the citation above. How we work →
Original publication title: Tolerability and pharmacokinetic profile of a novel benzene-poly-carboxylic acids complex with cis-diammineplatinum (II) dichloride in dogs with malignant mammary tumours.
- Species:
- dog
Plain-English summary
A group of seven dogs with mammary cancer received a new treatment called BP-C1, which is a combination of a chemical complex and a common cancer drug. The dogs were given this treatment daily for a week, followed by a week off, to see how well they tolerated it and if it helped reduce their tumors. While the dogs did not show a significant overall decrease in tumor size, some experienced temporary reductions. The treatment was generally well tolerated, and the dogs' overall health did not decline during the study.
People also search for: dog mammary cancer treatment · BP-C1 for dogs · side effects of cancer treatment in dogs
Abstract
The pharmacokinetic profile, tolerability and efficacy of benzene-poly-carboxylic acids complex with cis-diammineplatinum (II) dichloride (BP-C1) were studied in dogs with mammary cancer. A three-level response surface pathway designed trial was performed on seven dogs. At each level BP-C1 was administered subcutaneously daily for 7 days followed by a 7-day rest period in a dose escalating manner. Adverse events according to VCOG-CTCAE, performance status and tumour progression were recorded. The pharmacokinetic profile followed a two-compartment model with rapid absorption, short distribution, and a slow elimination phase. The overall elimination half-life was 125 h. The maximum tolerated dose of BP-C1 was estimated to be above 0.46 mg kg. A significant reduction in VCOG-CTCAE toxicity which correlated negatively with increasing dose was found. The dogs' general performance status remained unchanged. No decrease in total tumour burden was found, although temporary tumour reduction was seen in some target tumours.
Find similar cases for your pet
PetCaseFinder finds other peer-reviewed reports of pets with the same symptoms, plus a plain-English summary of what was tried across them.
Search related cases →Original publication on PubMed: https://pubmed.ncbi.nlm.nih.gov/25764447/